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Although several oropharyngeal cancer (OPC) susceptibility loci have been identified, most
previous studies lacked detailed information on human papillomavirus (HPV) status. We
conduct a genome-wide analysis by HPV16 serology status in 4,002 oral cancer cases (OPC
and oral cavity cancer (OCC)) and 5,256 controls. We detect four susceptibility loci pointing
to a distinct genetic predisposition by HPV status. Our most notable finding in the HLA
region, that is now confirmed to be specific of HPV(+)OPC risk, reveal two independent loci
with strong protective effects, one refining the previously reported HLA class II haplotype
association. Antibody levels against HPV16 viral proteins strongly implicate the protective
HLA variants as major determinants of humoral response against L1 capsid protein or E6
oncoprotein suggesting a natural immune response against HPV(+)OPC promoted by HLA
variants. This indicates that therapeutic vaccines that target E6 and attenuate viral response
after established HPV infections might protect against HPV(+)OPC.
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Oropharyngeal cancers (OPC) are a heterogeneous groupof tumors with some caused by smoking and excessivealcohol consumption and others by human papilloma-
virus (HPV) infections. The majority of HPV-positive OPC are
caused by HPV type 16 (HPV16), with HPV surpassing tobacco
exposure as the leading cause of OPC in many countries1,2.
HPV16-positive (HPV(+)) OPC are now considered a separate
disease entity, with different treatment regimen, and different
biological, epidemiological, clinical, and prognostic characteristics
from HPV16-negative (HPV(−)) OPC1,3–6.
Germline genetic variants are likely to play different roles in
susceptibility to HPV(+) and HPV(−) OPC and identification of
specific variants may help in the development of effective pre-
vention, screening, and treatment strategies. Genome-wide asso-
ciation studies (GWAS) have identified several susceptibility loci
for OPC, but have generally been limited by lack of information
on HPV status7–9. In our previous study, the effect of the human
leukocyte antigen (HLA) region (6p21.3), specifically the HLA
haplotype DRB1*13:01-DQA1*01:03-DQB1*06:03, was found to
be protective for OPC9. The same haplotype was previously
reported to be protective for cervical cancer10, and this further
highlights the need for comprehensive genetic analyses of OPC by
HPV status.
To achieve this, correct identification of HPV-driven oro-
pharyngeal tumors is critical. HPV serology is an appropriate
solution in situations where tumor tissue for direct assessment is
not available. It captures humoral immune response levels via
measurement of antibodies against viral proteins. Antibodies
against HPV L1 are considered to represent cumulative past and
present HPV infection from multiple possible anatomic sites (i.e.,
genital, anal, or oral), and are relatively common in individuals
without an HPV-related tumor2,6,11–13. Antibodies against HPV
E6 and E7 oncoproteins occur in response to an underlying HPV-
driven neoplastic process and are therefore expected to be at high
levels among those with an HPV-driven tumor and low levels
among cancer-free individuals. Large population-based cohort
studies have demonstrated the potential of serology measures
against HPV16 early viral proteins to detect individuals with
HPV16‐driven OPC with a high sensitivity and specificity14,15. In
particular, HPV16 E6 antibodies have been shown to occur in
more than 90% of those with HPV16(+) OPC while ser-
oprevalence among population controls is a rare condition
(<1%)2,14,16,17. Consequently, antibodies against specific E pro-
teins are useful in determining tumor HPV status2,6,16. In addi-
tion, they may also provide information on what humoral
responses are activated in response to infection and malignant
progression.
In this work, we conduct a GWAS in OPC stratified by HPV
status based on HPV16 serology to examine genetic architecture,
predisposition, and potential functional consequences of the
associated loci to develop insights into OPC etiology. Our study
identifies OPC genetic heterogeneity by HPV16 status and
implicates the HPV(+)OPC protective HLA variants as major
determinants of humoral response against viral proteins.
Results
Following stringent quality-control steps on genotyping data9,
1643 OPC cases and 5256 cancer-free controls remained for
analyses (Table 1, Supplementary Tables 1–3). The OC case series
comprised 2359 cases and was used to complement HPV(−)OPC
analyses given their common risk factors (Supplementary
Table 4).
Based on the serology data, 65.6% of the OPC cases (1078 of
1643) were classified as HPV(+). Among the controls with ser-
ology data available (1543), 16 (1%) were classified as seropositive
for HPV16; thus, the population specificity was 99.0% (95% CI:
98.3–99.4%). Median fluorescence intensity (MFI) values of
HPV16 serology markers (E1, E2, E7) were markedly higher in
cases compared to controls (Supplementary Table 5).
GWA analyses stratified by HPV16 status (1078 HPV(+) and
565 HPV(−) OPC cases, and 5256 controls) within each con-
tinent and meta-analyzed yielded 7,574,753 SNPS for risk asso-
ciation analyses. GWAs results of the two traits are presented in
Fig. 1. There was no evidence of genomic inflation for any of the
analyses after scaling it to 1000 cases and controls9 (Supple-
mentary Fig. 1). All findings with a P value less than 1 × 10−6 are
reported in Supplementary Data 1–3.
The HLA region is significantly associated with HPV(+)OPC
risk. A strong signal (P= 4.5 × 10−11) mapped to 6p21.32 was
identified for HPV(+)OPC cases (Fig. 1; Table 2). This area of the
genome encodes the HLA region, which regulates the immune
response. In addition, two suggestive associations at locus 3q26.1
Table 1 Background characteristics of the participating










Europe 730 (44.4) 2927 (55.7)
North America 913 (55.6) 2329 (44.3)
Age 0.07
≤50 293 (17.84) 889 (16.91)
51–60 687 (41.84) 1561 (29.7)
61–70 486 (29.6) 1649 (31.37)
>70 176 (10.72) 1157 (22.01)
Unknown 1 0
Sex <0.001
Male 1332 (81.1) 3334 (63.4)
Female 311 (18.9) 1922 (36.6)
Unknown 0 0
Smoking status <0.001
Never 391 (25.9) 2019 (40.9)
Former 640 (42.4) 1821 (36.9)
Current 479 (31.3) 1096 (22.2)
Unknown 133 320
Drinking status
Never 249 (16.8) 846 (17.8) 0.09




Positive 1078 (65.6) 16 (1.0)





Positive 1059 (64.5) 15 (1.0)
Negative 584 (35.5) 1528 (99.0)
Unknown 0 3713
HPV 16 L1 <0.001
Positive 767 (46.7) 64 (4.2)
Negative 875 (53.3) 1477 (95.8)
Unknown 1 3715
OPC cases definition: C01.9, C02.4, C05.1, C05.2, C09.0-C10.9.
aLogistic regression models were implemented to test associations of each variable
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and 4q35.1 were detected just below the GWAS significance level
(P < 1 × 10–7, Supplementary Table 6).
Stratified analyses, by study characteristics are summarized in
Supplementary Fig. 2. No evidence of differences in effect size
between characteristic strata were observed.
Of note, in this larger study population with HPV status
information, we also replicated the previously observed associa-
tion of three HLA-specific alleles (DRB1*13:01, DQA1*01:03, and
DQB1*06:03) and their haplotype with decreased HPV(+)OPC





Fig. 1 Genome-wide association regional meta-analysis results. Red line correspond to P= 5 × 10−8. The y axes show −log10 P values. a HPV(+)OPC
cases analysis with 1078 cases and 5256 controls. b HPV(−)OPC cases analysis with 565 cases and 5256 controls. GWAs for each world region were
performed using multivariable unconditional logistic regression assuming a log-additive genetic or dosage model with age, sex, and eigenvectors as
covariates. P-values are shown from fixed-effect meta-analysis of regional association statistics. HPV human papillomavirus, OPC oropharyngeal cancer.
Table 2 Top genome-wide significant regions and their most likely functional variants from regional meta-analyses of
oropharyngeal cancers by HPV16 seropattern status.
Independent
regions
Locus Variant Infoa EA/
OAb
Frequency (%) Meta-analysisc
Controls/Cases OR (95% CI) P value Q_p
HPV(+)OPCd
HLA class I
Intergenic rs4713462 genotyped A/G 32.6/21.3 0.66 (0.59–0.75) 4.5 × 10−11 0.19
HLA-B 1501 0.97 P/A 5.9/3.0 0.44 (0.33–0.58) 1.13 × 10−8 0.20
156 -Trp 0.98 P/A 6.1/3.2 0.45 (0.34–0.59) 1.05 × 10−8 0.21
HLA class II
Class II haplotype DRB1*1301-DQA1*0103-
DQB1*0603
P/A 6.7/2.6 0.42 (0.31–0.56) 7.4 × 10−9 0.86
HLA-DRB1 1301 0.99 P/A 6.7/2.8 0.43 (0.32–0.58) 1.44 × 10−8 0.95
71 -Glue 0.94 P/A 14.5/7.9 0.56 (0.47–0.68) 2.8 × 10−9 0.30
HLA-DQA1 0103 1 P/A 7.8/3.1 0.45 (0.34–0.59) 8.7 × 10−9 0.90
HLA-DQB1 0603 0.98 P/A 7.3/3.1 0.45
(0.34–0.60)
3.1 × 10−8 0.35
HPV(-)OPCf
12q23.3 BTBD11 rs35189640 0.94 T/C 2.0/4.7 2.73 (1.97–3.79) 1.1 × 10−9 1
HLA human leukocyte antigen, OR odds ratio, 95% CI confidence interval, Q_p Cochran’s heterogeneity p value
aImputation INFO (R2) is the average across imputation batches.
bEffect allele/other allele; P stands for presence and A stands for absence for amino acid polymorphisms and HLA alleles.
cRegional meta-analyses Europe and North America.
dNumber of subjects: 1078 HPV(+)OPC and 5256 controls.
eamino acid change due to rs9269942 C/A [Ala (GCG) --> Glu (GAG)].
fNumber of subjects: 565 HPV(−)OPC negative and 5256 controls.
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Fine-mapping of the HLA region reveals two independent loci
associated with risk of HPV(+)OPC. The HLA region is highly
polymorphic with extensive linkage disequilibrium (LD) and
assessing the causality of identified associations is difficult. To
fine-map the region, we therefore imputed sequence variation in
classical HLA genes. The final set of imputed variants used in
association analyses were of high quality; 92.5% of the variants
had R2 ≥ 0.9, and 68.2% of the less common variants (MAF <
0.05) had R2 ≥ 0.9.
Associations with risk of HPV(+)OPC extended into the class I
and II regions (Fig. 2a). The most significant variant was the A
allele of rs4713462, an HLA class I intergenic variant that maps
5.6 kb 5′ of AL671883.1. This variant had not been identified in
the previous GWAs analysis9 in which HPV status data was
available for only a limited number of cases. (OR= 0.66,
P= 4.5 × 10−11; Fig. 2a; Table 2). Given its proximity with
HLA-B and -C, we examined pairwise LD statistics across single
nucleotide polymorphisms (SNPs) covering this region in our
data. In Supplementary Fig. 12, pairwise D′ and R2 indicate that
SNP rs4713462 showed generally modest correlation with SNPs
in HLA-B and C coding regions or surrounding areas. This is in
line with our results in Supplementary Fig. 13, where rs4713462 is
the most significant variant in the region with modest LD and
association statistics with the variants covering HLA-C and B.
Functional annotation revealed that rs4713462 is predicted to be
an eQTL for HLA-C across different tissues including upper
digestive tract tissues. Given the extended LD in the MHC region
and the considerable number of variants below genome-wide
level significance showing similar associations with HLA-C
mRNA levels (Supplementary Table 7), we explored HLA-C
expression genetic control across the MHC region. There did not
appear to be a consistent association between the rs4713462 A
allele and HLA-C gene expression in oral related tissues
(Supplementary Fig. 3). This may suggest that HLA-C expression
alone is unlikely to be mediating this association.
After conditioning on rs4713462, evidence remained of
another protective association for the HLA class II region
(P < 5 × 10−8). This mapped to an A allele of rs9269942, a
multiple nucleotide variation that results in an amino acid change
to glutamine in codon 71 (71-Glu) of HLA-DRB1 protein
(OR= 0.56, P= 2.8 × 10−9; Fig. 2b, Table 2) and translates to a
location in the peptide-binding groove of HLA-DRB1*13:01 and
in three other HLA-DRB1 alleles (*04:02, *13:02 and *11:02) for
which a protective trend was also identified (Supplementary
Fig. 4; Supplementary Table 8). This result further reinforces the
possible functional role of this variant and refines the association
of the HLA haplotype DRB1*13:01-DQA1*01:03-DQB1*06:03
identified in our previous GWAs analysis for OPC9 and with
decreased cervical cancer risk10.
When both rs4713462 and HLA-DRB1 71-Glu were condi-
tioned on, no remaining signals were detected (Fig. 2c).
In addition to identifying loci associated with HPV-positive
OPC risk, haplotype analysis was used to define the boundaries of
associated variants within the HLA region given its complexity
and extended LD. The only haplotype found associated with OPC
risk was the HLA class II haplotype, DRB1*13:01-DQA1*01:03-
DQB1*06:03 (Table 2; Supplementary Fig. 1a). No other haplotype
showed a significant association when considering Class I or both
Class I and Class II blocks. Conditional analyses considering
DRB1*13:01-DQA1*01:03-DQB1*06:03 and rs4713462 in the
same model, also revealed the independence of both effects
(Table 3).
We subsequently assessed whether the independent variants
identified to be protective of OPC were indicative of a protective
effect from a haplotype, from specific amino acids within
haplotypes, or from the variants themselves which could be
functionally mapped to other variants unrelated to HLA
(Supplementary Table 11). To refine the associations within the
MHC region, model selection was used to identify the combina-
tion of variant, amino acid and/or haplotype that best explained
the data using BIC (Bayesian Information Criterion) as model
selection criterion. Table 3 displays the combined models with the
best fit to the data from this search. Model A was considered the
best fitting model. This implies that the amino acid 71-Glu in
HLA-DRB1*13:01 explains the association of the class II
haplotype DRB1*13:01-DQA1*01:03-DQB1*06:03 with risk of
HPV(+)OPC (Table 2; Table 3; Supplementary Fig. 2a).
Although Glu-71 accounted for the main part of the effect of
DRB1-DQA1-DQB1 as it fitted the data in the conditional model
and it has biological significance, amino acid (Ala-74) does not
seem to be an independent effect on Glu-71 since the effect was
not significant (p > 5 × 10−8) and weaker when both are in the
model (Supplementary Table 12, model E), whereas the effect was
stronger and significant in the absence of Glu-71 (Supplementary
Table 12, model C) and in the individual model (Supplementary
Table 11). For that reason, we cannot exclude additional loci
within the haplotype supporting or contributing additively to risk,
as probably is happening with the amino acid position 74 in
HLA-DRB1*1301, also located in the protein binding groove
(Supplementary Fig. 4).
Association of each HLA variant with antibodies against viral
proteins suggests differential HLA response to viral proteins.
We conducted a protein quantitative trait loci (pQTL) analysis of
8291 MHC imputed variants using HPV16 E6 or L1 antibody
levels in all OPC patients to explore associations between these
variants and antibody levels. Rs4713462 and 71-Glu were the
variants most strongly associated with E6 and L1 antibody levels,
respectively (Fig. 3, Supplementary Fig. 9). Specifically, results
showed that the rs4713462 allele (A) was exclusively and strongly
associated (B=−0.31, P= 1.3 × 10−8) with lower E6 antibody
levels and not with L1 MFI levels (B=−0.07, P= 0.05); 71-Glu,
which is located in the peptide-binding groove of HLA-
DRB1*13:01, showed a robust association (B=−0.30,
P= 7.0 × 10−8) with lower L1 MFI levels but no correlation with
E6 MFI levels (B=−0.12, P= 0.11). This suggests that their
association with HPV(+)OPC could potentially be mediated via
influencing humoral immune response during viral tumorigenesis
and corroborates the independence of these variants in their
associations with lower risk of HPV(+)OPC.
We repeated the analyses for the top associated variants in the
subset of OPC cases classified as HPV(+) expecting to find a
similar association to the one using all OPC cases. Analyses
restricting to HPV16 E6+ cases (>1000 MFI) captured again the
association with rs4713462 (B=−0.1; P= 0.01). The association
was less significant as expected given the smaller numbers and
reduced range of data (Supplementary Fig. 11). We did not see
association with the 71-Glu variant and L1 levels when restricting
to the HPV16 L1+ cases (B=−0.04; P= 0.22). This could again
be explained by the more limited data range when one restricts to
L1+ cases (Supplementary Fig. 11).
Combined seropositivity to HPV16 E6 and L1 was relatively
common among OPC cases (in 42%, 685 of 1643 OPC). We
therefore investigated the possible influence of E6 or L1 antibody
levels on their association with the respective genetic variant by
adjusting for the alternative serology marker. As shown in
Supplementary Table 11, results are extremely similar to the
original results in Fig. 3, indicating that adjustment by the other
serology marker makes little difference.
Due to the functional connection and correlation of other E
proteins (E1, E2, E7) with HPV16 E6, we explored the relationship
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26151-9
4 NATURE COMMUNICATIONS |         (2021) 12:5945 | https://doi.org/10.1038/s41467-021-26151-9 | www.nature.com/naturecommunications










































1,078 OPC HPV posive / 5,256 controls
1,078 OPC HPV posive / 5,256 controls







Fig. 2 Plots of stepwise conditional association in the MHC region for HPV(+)OPC cases. a–c The association for each locus used for conditioning is
shown in each panel: a unconditioned, b conditioned on rs4713462, c conditioned on rs4713462 and HLA-DRB1 amino acid change in position 71 (71-Glu).
Detailed association results in Table 2 and Supplementary Fig. 2. Circles represent –log10 (P values) for each binary marker using the imputed allelic
dosage (between 0 and 2) and genotyped variants. Multivariable logistic regression assuming a log-additive genetic or dosage model with age, sex, and
eigenvectors as covariates was used as baseline model. The dashed black horizontal lines represent the study-wide significant threshold of P= 5 × 10−8.
The physical positions of HLA genes on chromosome 6 are shown at the bottom. The color of the circles indicates the type of marker; light blue—SNPs
outside and within HLA genes, green - classical HLA alleles and red—amino acid polymorphisms of the HLA genes. HLA human leukocyte antigen, MHC
Major Histocompatibility Complex, HPV human papillomavirus, OPC, oropharyngeal cancer.
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between the top associated HLA variants and antibodies
against these proteins as a sensitivity analysis. We also
explored association with other well-known but less common
high-risk HPV types (E6 and E7 of HPV18/31/33/35/45/52/
58) to assess the question of whether the identified HLA
variants are E6 specific associated variants independent of
HPV type. Our results suggest that the rs4713462 association
might be specific to HPV16 E6 antibodies given that the
strongest association was still the one detected with HPV16
E6 (Supplementary Fig. 6). Seropositivity for other HPV high-
risk types represents a very limited fraction among HPV(+)
or HPV(−)OPC reducing the chances for non-HPV16
markers to explain HLA genetic findings (Supplementary
Tables 9 and 10).
HPV(−)OPC GWAS. In the GWA analyses within HPV(−)OPC
cases and controls, a risk variant at 12p23.3 (rs35189640, OR=
2.73, P= 1.1 × 10−9; Fig. 1b; Table 2) was found significantly
associated with risk of HPV(−)OPC. Genomic annotation
revealed that rs35189640 is an intronic variant in the BTB
domain-containing 11 (BTBD11), a DNA-binding protein such as
zinc-finger transcription factors. Interestingly, rs35189640 also
maps into a repressed Polycomb-group protein (PcG) binding site
specific to epithelial tissue based on chromatin states evaluated in
more than 30 tissues (Supplementary Fig. 5). No evidence for
heterogeneity was detected by geographic region or study char-
acteristics displayed in Table 1 (Supplementary Fig. 2d). Other
suggestive susceptibility variants were found at five additional
loci at 3p26.2, 1p36.13, 13q33.3, 5q34, and 6p21.32 that fell just
Table 3 HLA alleles, SNP and amino acids contained in the best models obtained from HPV(+)OPC analyses as judged by the
BIC criterion.
Model Locus OR (95%CI)a P value BIC BIC difb
A rs4713462+DRB1 (71-glu) 4454 0
rs4713462 0.67 (0.59-0.76) 1.46 × 10−10
DRB1 (71-glu)c 0.55 (0.46-0.67) 1.03 × 10−9
B rs4713462 + Class II Haplotype 4465 +11
rs4713462 0.66 (0.58-0.75) 5.52 × 10−11
DRB1*1301-DQA1*0103-
DQB1*0603
0.45 (0.34-0.61) 1.13 × 10−7
HLA-B*1501 + Class II Haplotype 4489 +35
HLA-B*1501 0.53 (0.40-0.71) 1.77 × 10−05
DRB1*1301-DQA1*0103-
DQB1*0603
0.43 (0.32–0.58) 3.23 × 10−8
B (156) + Class II Haplotype 4489 +35
B (156) 0.54 (0.41-0.71) 1.53 × 10−05
DRB1*1301-DQA1*0103-
DQB1*0603
0.43 (0.32–0.58) 3.05 × 10−8
BIC Bayesian information criterion, HLA human leukocyte antigen, OR odds ratio, 95% CI confidence interval
aObtained from multivariate logistic regression assuming an additive genetic model with sex and principal components as covariates.
bModels having their BIC difference within: +1–2 of the minimum have substantial support; +4–7 of the minimum have considerably less support; BIC > 10 above the minimum fail to explain some
substantial structural variation in the data.
cAlleles where these amino acids are part of the sequence: 71(Glu) in DRB1*1301 and also in *0402, *1302, and *1102.
a b
B= -0.31













































































Fig. 3 pQTL analysis of plasma antibody levels against HPV proteins of the top two associated HPV(+)OPC HLA variants. Box plots showing a HPV16
E6 MFI levels and rs4713462 genotypes, and b HPV16 L1 MFI levels and DRB1 (71-Glu) variants in OPC cases. Effect sizes (B, regression coefficient) were
adjusted for age, sex, and eigenvectors. For HLA-DRB1 71-Glu, A stands for absence and P stands for presence. Box plots show the medians (center lines)
and the 25th and 75th percentiles (box edges), with whiskers extending to 1.5 times the interquartile range. Linear multivariate models were implemented
to test associations of genetic variants across the MHC region with HPV16 L1 or E6 log-transformed MFI levels, assuming a dosage model with age, sex and
eigenvectors as covariates. HLA human leukocyte antigen, pQTL protein Quantitative Trait Loci, HPV human papillomavirus, OPC oropharyngeal cancer,
MFI median fluorescence intensity.
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under the GWA significance level (P < 1 × 10–7, Supplementary
Table 6).
Pooled GWAs of OCC and HPV(−)OPC cases. To improve
power and test the reproducibility of our findings, we pooled 2359
oral cavity cancer (OCC) cases with the 565 HPV(−)OPC cases
and repeated the analyses. This was done under the assumption
that OCC is a predominately HPV(−) disease and has risk factors
in common with HPV(−)OPC, i.e., tobacco and alcohol usage.
Manhattan plots for the pooled dataset are displayed in
Supplementary Fig. 7. In addition to previously reported variants9
for both cancer sites, we identified two susceptibility loci at
6p21.32 (rs3828805, OR= 0.77, P= 2.5 × 10−9) and 15q21.2
(rs10851478, OR= 1.22, P= 1.3 × 10−8) common to both cancer
entities. The rs3828805 is in LD with HLA-DRB1 71-Glu variant
(r2= 0.48) that we found to be associated with HPV16 L1
antibody levels in HPV(+) OPC. As expected, rs4713462, which
was found exclusively associated with antibodies against the
HPV16 E6 viral oncoprotein and is independent from rs3828805
(r2= 0.0004), was not associated with risk of OC/OPC(−)
(Table 4). Regarding rs10851478, this variant is a cis-eQTL for
the FGF7 gene (Supplementary Fig. 8) which is a potent epithelial
cell-specific growth factor with an important role in morphogen-
esis of epithelium.
Assessment of the consistency of effects across studies. Overall,
heterogeneity tests showed that HPV(−)OPC and OC share their
top disease-related genetic associations while those for HPV(+)
and HPV(−)OPC were different revealing a different genetic
predisposition and probably genetic architecture (Supplementary
Fig. 10). In brief, significant heterogeneity (p < 0.05) was identi-
fied in the meta-analysis of HPV(+) and HPV(−)OPC for
rs4713462 at HLA region and for rs35189640 at BTBD11 locus
suggesting an exclusive association with HPV(+) and HPV(−)
OPC, respectively (Supplementary Fig. 10b). FGF7 and LHPP
association showed common and consistent effects to the HPV(-)
OPC and OCC analyses (Supplementary Fig. 10a) as well as
ADH1B that was previously identified as associated with overall
OPC and OCC9. BTBD11 showed a stronger effect for HPV(−)
OPC (Supplementary Fig. 10).
Discussion
Overall, our study identified OPC genetic heterogeneity by
HPV16 status and expands existing knowledge of the genetics of
oral cancers identifying several genetic loci.
Two loci in the HLA region showed the strongest protective
effects against HPV(+)OPC risk: rs4713462 and an amino acid
polymorphism in HLA-DRB1 71-Glu. The latter refines the
previously reported HLA class II haplotype association recently
replicated in an independent series9,18. Using HPV serology data,
rs4713462 was exclusively associated with antibody levels against
HPV16 E6, the viral oncoprotein, while HLA-DRB1 71-Glu was
only associated with antibody levels against HPV16 L1, the viral
capsid protein.
In our current understanding, HPV seropositivity is the result
of a humoral immune response to a viral protein in those indi-
viduals trying to mount a T-cell response to eliminate affected
cells19,20. T-cell-mediated immune responses are essential for the
clearance of both HPV infection and HPV-driven tumor cells and
one may speculate that the associated HLA variants are
promoting a targeted cell-mediated response to viral proteins
which confers the protective effect against an HPV-driven cancer.
Indeed, the relatively lower MFI levels of L1 or E6 in those
individuals carrying the HLA-DRB1 71-Glu or the A allele of
rs4713462 respectively may be explained by more active
“consumption” of antibodies when the T cell sees its antigen
reflecting an active immune reaction21,22. Consequently, the
HLA-DRB1 71-Glu variant may implicate a more effective control
of preventing an HPV16 infection that ultimately protects against
HPV-driven cancers. This would be mimicking the effect of
prophylactic vaccines which are exploiting the role of L1 capsid
protein in initiating a tissue-specific infection and its antigenicity
or maybe inducing a more effective T-cell response against L1
and thus preventing oncogenic transformation. The A allele of
rs4713462 may be acting at a later stage through a targeted cell-
mediated response to viral carcinogenesis provided by HPV16-
infected cells (over)expressing E6. Therefore, our results provide
evidence of natural immune response promoted by HLA germline
variants against HPV-driven tumors at different stages of
the infectious process that leads to cancer. This suggests, in the
case of the E6-related variant, that a therapeutic vaccine targeting
HPV16 E6 may attenuate viral impact after established HPV
infections23. Several promising approaches have been developed,
with some having achieved advanced clinical trial stages24–27.
Oncoproteins E6 and E7 have been widely used in therapeutic
HPV vaccine studies, given that the HPV16 E6 and E7 proteins
are both drivers of unchecked cell proliferation in the most
common oncogenic HPV types and are constitutively expressed.
HPV vaccines using E7 alone have been more commonly used
than E6. The fact that E7 is more abundantly expressed and
highly conserved makes it a priori a better candidate, but it is a
poorly immunogenic protein in reality. Our results put a parti-
cular emphasis on the potential of protein/peptide vaccines
against E6. However, combination with other therapies targeting
regulatory mechanisms and local immunosuppression in the
tumor microenvironment, might be necessary for cancer ther-
apeutic vaccination to become clinically successful.
Table 4 Top genome-wide significant regions and the highlighted ones in previous analysis from regional meta-analyses of OCC
and HPV(-)OPC pooled analysis.
Genomic regions Locus SNP Infoa EA/OAb Meta-analysisc
OR (95%CI) P value Q_p
6p21.32 HLA region rs3828805 0.88 T/C 0.77 (0.71–0.83) 2.5 × 10−9 0.71
rs4713462 Genotyped A/G 1.02 (0.95–1.10) 0.61 0.10
4q23 ADH1B rs1229984 Genotyped A/G 0.59 (0.49–0.71) 4.1 × 10−8 0.11
10q26 LHPP rs201982221 Genotyped D/I 1.74 (1.43–2.13) 4.8 × 10−8 0.28
12p23.3 BTBD11 rs35189640 0.94 T/C 1.79 (1.45–2.21) 7.5 × 10−8 0.54
15q21.2 FGF7 rs12910284 0.99 G/A 1.22 (1.14–1.30) 1.5 × 10−8 0.18
OR odds ratio, 95% CI confidence interval, Q_p Cochran’s heterogeneity p value.
aImputation INFO (R2) is the average score across imputation batches.
bEffect allele/other allele; “D” stands for deletion and “I” stands for insertion.
cRegional meta-analyses Europe and North America with a total number of subjects: 2923 patients and 5256 controls.
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The HPV(−)OPC analysis revealed one association at 12p23.3
in BTBD11 and showed shared genetic links with OCC identi-
fying two risk loci in addition to those that were already known:
6p21.32 and 15q21.2. Functional evidence at 12p23.3 was
limited, even though we found that the BTBD11 variant
maps into a tissue-specific PcG protein binding site and nearby
a transcription starting site. This suggests a potential impairment
of transcription regulation increasing risk for epithelial
malignancies28–30. At 15q21.2, rs10851478 showed a significant
risk effect to develop HPV(−) oral cavity cancers and also tend to
be a cis-eQTL for the FGF7 gene specific of fibroblasts. FGF7 is a
potent epithelial cell-specific growth factor with an important role
in morphogenesis of epithelium suggesting this variant as one of
the malignancy-contributing factors from tumor stroma31,32.
A limitation of the current study is the relatively modest
sample size for some of the analyses. However, the inclusion of a
rich collection of data partially compensates this limitation. For
HPV(+)OPC, convergent evidence of association from distinct
approaches (GWAs and pQTL) identify the same variants
within HLA as the best associated variants in relation with
HPV infection. For HPV(-) cancer the statistical power conferred
by using a second dataset with potential genetic links has
allowed us to support the discovery of additional genome-wide
significant SNPs.
To conclude, the results generated in this study are important
for understanding the biology of oral and OPC. Although future
functional analyses are needed to confirm the impact of our
findings, we provide extensive information on the likely con-
sequences of relevant genetic variants putting forward a rich set of
plausible gene targets and biological mechanisms for functional
follow-up for both HPV(+)OPC and HPV(−)OPC and OCC
cancers. In particular, our findings enhance the role of HLA
variants in the immune pathogenesis of HPV(+)OPC, and may
also have implications for cancer immunotherapies such as HPV-
targeted vaccines that are currently undergoing clinical
evaluation.
Methods
Subjects, specimens, and genotypes. A total of 1643 OPC cases (included ICD
codes: C01.9, C02.4, and C09.0–C10.9) and 5256 controls were included in this
study (Table 1). All study participants were of European ancestry and came from
10 epidemiological studies from North America and Europe included in the so-
called OncoArray study published earlier in 20169 (Supplementary Table 1).
Subjects were genotyped using the Illumina OncoArray. Plasma samples utilized
for HPV status determination were obtained from HPV unvaccinated subjects at
time of diagnosis and prior to start of treatment for OPC cases, and at time of
enrollment for controls.
The Oncoarray study also includes OCC (included ICD codes: C02.0–C02.9
(except C02.4), C03.0–C03.9, C04.0–C04.9, C05.0–C06.9). In contrast to OPC,
HPV is thought to play a very limited role in OCC, with an estimated prevalence of
5% or less in most populations33,34. In this regard, OC shares risk factors with
HPV(−)OPC, namely tobacco and alcohol usage. We therefore hypothesized that
HPV(−)OPC and OCC may share genetic risk factors and, to expand the study
population for HPV(−) tumors, pooled together the series of 2,359 OCC cases and
565 HPV(−)OPC and performed a GWA analysis (Supplementary Table 4).
Ethics statement. Each included study was approved by their corresponding local
ethics committee/Institutional Review Board, and informed consent was obtained
from all study participants to undertake serological analyses which were not cov-
ered in our previous study9. In addition, the International Agency for Research on
Cancer Institutional Review Board (IARC-IRB; reference 16–34) evaluated and
approved inclusion of each contributing study into the current study
Imputation and HLA fine mapping. For all subjects, individual-level genome-wide
SNP data were available9. Imputation was performed using the Michigan Impu-
tation Server35 with the Haplotype Reference Consortium panel36. SNPs with
minor allele frequency (MAF) < 0.01 or R2 < 0.3 in any of the batches were
excluded before association analyses. Taking advantage of the high OncoArray SNP
coverage in the HLA region, we used the genotyping data from 25 to 35 Kb at
chromosome 6 (NCBI build 37) to impute 8,961 HLA variants (including classical
two and four digit HLA alleles and amino acid polymorphisms of the HLA genes
along with the SNPs across MHC region) that were not directly genotyped. For
this, we utilized the reference data collected by the Type 1 Diabetes Genetics
Consortium (T1DGC)37,38 using the SNP2HLA v1.0.3 package in Beagle software
v339,40. We applied post-imputation QC criteria of R2 < 0.3 to exclude variants
from the association analysis. All the evaluated HLA variants were defined as
binary markers in the analyses as follows: (a) For biallelic SNPs, classical HLA
alleles and binary amino acid positions, the effect allele or variant was the minor
allele, the presence of the HLA allele or the presence of the less frequent amino
acid, respectively; (b) For multi-allelic amino acid positions, composite markers
were defined where each possible individual allele and combination of alleles was
tested for association.
Serological analyses and HPV status determination. Plasma samples were
analyzed at the German Cancer Research Center (DKFZ; Heidelberg, Germany)
using multiplex serology by laboratory staff blinded to the case–control status and
cancer site of the subjects41. Briefly, viral antigens were affinity-purified, bacterially
expressed fusion proteins with N-terminal Glutathione S-transferase. Biotinylated
secondary antibodies (Jackson ImmunoResearch Laboratories, reference: 109-065-
064) were used in a 1:1000 dilution as reporters to detect bound plasma antibodies.
Samples were evaluated at a final 1:100 dilution for antibodies against the HPV16
oncoproteins E6 and E7, other viral regulatory proteins (E1, E2), and the major
capsid protein L1 as well as for antibodies against proteins from other high-risk
HPV types (HPV18/31/33/35/45/52/58) (Supplementary Table 5). MFI values were
dichotomized as antibody positive or negative for HPV16 proteins using predefined
cutoff values, that is 1000 MFI (E6), 548 MFI (E7), 200 MFI (E1), 679 MFI (E2)
and 422 MFI (L1)6,14. OPC cases were classified as HPV(+) or HPV(−) based on a
previously validated HPV16 seropattern algorithm14 with HPV(+) defined as
follows: HPV16 E6 > 1000 or 3 out of 4 E proteins greater than their cutoff value
(HPV16 E1 > 200 MFI, HPV16 E2 > 679 MFI, HPV16 E6 > 484 MFI, HPV16
E7 > 548 MFI). Subjects who did not fulfill the criteria for HPV(+) were classified
as HPV(−).
GWAS, regional meta-analyses. Regional meta-analysis (Europe and North
America) was performed to evaluate the relationship between SNPs and OPC risk
by HPV status and between SNPs and risk of OCC or HPV(−)OPC (pooled series
of OCC and HPV(−)OPC). In brief, GWAs for each world region were performed
for genotype dosages, using multivariable unconditional logistic regression
assuming a log-additive genetic or dosage model with age, sex, and eigenvectors as
covariates. Next, association statistics were included in a fixed-effect meta-analysis
performed in PLINK v1.0742. The P value for heterogeneity was calculated using
Cochran’s Q test. Conditional analyses within associated regions and meta-analysis
of regional results were performed using glm funtion in R software43 (v.3.6.3).
Assessment of the consistency of effects across studies. A test for hetero-
geneity (Cochran’s Q) was used to evaluate the consistency of the effects of the top
hits across GWAs by combining in a meta-analysis HPV(+) and HPV(−)OPC
results or HPV(−)OPC and OC after dividing the control group into two
equivalent random series.
Analysis within the MHC region. Phased genotypes obtained from the imputed
data were used to generate population-based haplotypes with the Haplo.stats R
package (v.1.7.7).
Each haplotype, allele, variant, and associated amino acid was individually
tested for an association with risk of OPC by HPV status within the statistical
framework and covariates defined previously (age, sex, and eigenvectors). Variables
that were independently associated with risk (HLA alleles and/or haplotypes, their
significant amino acids and SNPs) were assessed in multivariable risk models to
search for the best overall HLA model. First, we used a forward selection stepwise
regression of significant variants within the independently associated regions. For
each gene or region we looked for the set of significant amino acid positions and we
defined the classical alleles with consistent residues at those positions. We also
included as covariates in these risk models the top independently associated
markers identified within the HLA region from multivariable regression analyses.
Model selection for the best overall HLA predictors associated with risk was
conducted using the lowest BIC44,45.
The aim was to find the best set of amino acids and/or HLA alleles that were
independently associated with lung cancer as judged by the lowest AIC (Akaike
Information Criterion) and BIC.
Three-dimensional HLA ribbon models for the HLA-B and HLA-DR proteins
were prepared using UCSF Chimera v1.11.
Functional variant annotation. To identify potentially functional candidates a
comprehensive bioinformatic assessment of the SNPs with GWAS P value < 10−6
was performed. Using the HaploR R package, both HaploReg46 and RegulomeDB47
were crosschecked to explore data reflecting transcription factor binding, open
chromatin and the presence of putative enhancers. Further, the Genotype-Tissue
Expression dataset (GTEx v8)48 was interrogated to identify potential genes
influenced by disease-associated SNPs. For this purpose, GTEx v8 eQTL summary
statistics, based on RNAseq analysis, were obtained for tissues best representing
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oropharyngeal and oral cavity tissue in this platform (Esophagus mucosa of 497
individuals, Esophagus muscularis of 465 individuals, not sun-exposed skin of 517
individuals and cell-cultured fibroblasts of 483 individuals). Functional annotation
for variants reaching P < 5 × 10−8 is summarized in Supplementary Table 7.
Linkage Desequilibrium LD statistics (D′ and R2) of genomic regions of interest
were also examined in the reference European population from Phase 3 of the 1000
Genomes Project (1000G)49.
To evaluate potential overlap with published GWAS findings, results reported
in the NHGRI catalog50 were extracted on 2020-12-02 (containing 4795
publications and 222481 associations) and crosschecked against our results.
Protein quantitative trait loci (pQTL) of plasma antibodies levels against HPV
proteins. As mentioned, plasma antibody levels against HPV16 L1 are thought to
represent cumulative past and present HPV infection from multiple possible
anatomic sites11,13,51–53 while E6 antibody levels are accurate markers of malignant
HPV-related disease14,16,54. Considering the connection between antibody-
mediated immune responses and HLA-mediated antigen recognition, we explored
the impact of MHC genetic variants on the humoral response to HPV proteins on
the whole series of OPC cases. Linear multivariate models were implemented to test
associations of genetic variants across the MHC region with HPV16 L1 or E6 log-
transformed MFI levels, assuming a dosage model with age, sex, and eigenvectors
as covariates in OPC cases.
Technical validation of imputed SNPs. Technical validation of imputed findings
was performed in the recent GWAS study9. In addition, the HPV(−)OPC-asso-
ciated low-frequency variant at 12q23.3 (rs35189640) was successfully validated by
TaqMan assays (Thermo Fisher Scientific) in 1810 individuals (concordance of
99.9%).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are provided within
the paper and its supplementary information. Genotype data for the OPC and OC
OncoArray study have been deposited at the database of Genotypes and Phenotypes
(dbGaP) and are available under controlled access under accession phs001202.v1.p1. All
the projects are generally approved for non-commercial research and we ensure that the
proposed research complies with the signed agreements with research participants. The
oral and pharyngeal GWAS summary statistics by cancer site and world region have been
deposited in the IEU Open GWAS platform (https://gwas.mrcieu.ac.uk/) under the
GWAs IDs: ieu-b-89, ieu-b-90, ieu-b-94, ieu-b-96, ieu-b-93, ieu-b-97, ieu-b-91, ieu-b-95
and ieu-b-98. Protein Data Bank (RCSB PDB) structures for three-dimensional HLA
ribbon models can be obtain under accession codes 3pdo and 2bpv. Genotype-Tissue
Expression dataset (GTEx v8) is publicly available and can be downloaded following
instructions at [https://gtexportal.org/home/protectedDataAccess].
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